Linked e-resources
Details
Table of Contents
Intro
Preface
Contents
Part I: Challenges in Patient Preparation
1: Challenges in Patient Preparation
1.1 Introduction
1.2 Prolonged Intervals of Fasting
1.3 Dietary Modifications
1.4 Pharmacologic Approaches
1.5 Conclusion
References
Part II: Non-ischemic Diseases
2: Cardiac Sarcoidosis
2.1 Introduction
2.2 Screening for Cardiac Sarcoidosis
2.3 Diagnosis
2.4 Endomyocardial Biopsy: Imaging Guidance
2.5 CMR for Diagnosis/CMR Imaging Protocol
2.6 Late Gadolinium Enhancement (LGE)
2.7 Imaging Myocardial Inflammation and Quantitative Tissue Characterization with CMR T1 and T2 Mapping
2.8 Additional CMR Findings Suggestive of Cardiac Sarcoidosis
2.9 Differential Diagnosis
2.10 Treatment: Anti-Inflammatory Therapy
2.11 CMR for Arrhythmogenic Risk Stratification/ICD
2.12 Positron Emission Tomography
2.13 Positron Emission Tomography with Tracers Other than 18F-FDG
2.14 Prognosis
2.15 Follow-up and Monitoring of Anti-Inflammatory Response
2.16 Hybrid PET-CMR Imaging
2.17 Outlook
2.18 Conclusion
References
3: Cardiac Amyloidosis
3.1 Introduction
3.1.1 Different Phenotypes of Cardiac Amyloidosis
3.1.1.1 AL Amyloidosis
3.1.1.2 ATTR Amyloidosis
3.1.2 Screening for Cardiac Amyloidosis
3.2 Diagnosis
3.2.1 Endomyocardial Biopsy
3.2.2 Cardiac Magnetic Resonance (CMR) Imaging
3.2.2.1 CMR Diagnosis and Imaging Protocol
3.2.2.2 Late Gadolinium Enhancement (LGE)
3.2.2.3 Quantitative Tissue Characterization with CMR Native T1, T2 and ECV Mapping
3.2.2.4 Differential Diagnosis of AL vs. ATTR Amyloid
3.2.3 Scintigraphy
3.2.3.1 Bone Avid Radiotracers
Imaging Protocols and Interpretation
Diagnostic Accuracy
3.2.3.2 Innervation Radiotracers
3.2.4 Positron Emission Tomography (PET)
3.2.5 Hybrid Imaging: PET/MRI
3.2.6 Diagnostic Algorithm for Diagnosis and Sub-Typing of Cardiac Amyloidosis
3.3 Treatment
3.4 Prognosis
3.5 Conclusion
References
Part III: Ischemic Diseases
4: Molecular Imaging of Vulnerable Plaque
4.1 Introduction
4.2 Biology and Pathogenesis of Atherosclerosis
4.2.1 History
4.2.2 Mechanisms of Atherosclerosis
4.2.2.1 Initiation of Atherosclerosis
Vascular Endothelium and Atherosclerosis
Hemodynamics Forces in Atherosclerosis
Low-Density Lipoprotein Cholesterol
Surface Adhesion Molecules
Foam Cells Formation
Progression of Atherosclerosis
Smooth Muscle Cells and Atherosclerosis
Calcification
Plaque Neoangiogenesis
Innate Immunity Cells in Atherosclerosis
Adaptive Immunity in Atherosclerosis
4.2.3 Complication of Atherosclerosis
4.2.3.1 Inducible Ischemia
4.2.3.2 Plaque Rupture
4.2.3.3 Plaque Erosion
4.3 Metabolism of Glucose in Atherosclerosis
4.3.1 Glucose and Immune Cells
Preface
Contents
Part I: Challenges in Patient Preparation
1: Challenges in Patient Preparation
1.1 Introduction
1.2 Prolonged Intervals of Fasting
1.3 Dietary Modifications
1.4 Pharmacologic Approaches
1.5 Conclusion
References
Part II: Non-ischemic Diseases
2: Cardiac Sarcoidosis
2.1 Introduction
2.2 Screening for Cardiac Sarcoidosis
2.3 Diagnosis
2.4 Endomyocardial Biopsy: Imaging Guidance
2.5 CMR for Diagnosis/CMR Imaging Protocol
2.6 Late Gadolinium Enhancement (LGE)
2.7 Imaging Myocardial Inflammation and Quantitative Tissue Characterization with CMR T1 and T2 Mapping
2.8 Additional CMR Findings Suggestive of Cardiac Sarcoidosis
2.9 Differential Diagnosis
2.10 Treatment: Anti-Inflammatory Therapy
2.11 CMR for Arrhythmogenic Risk Stratification/ICD
2.12 Positron Emission Tomography
2.13 Positron Emission Tomography with Tracers Other than 18F-FDG
2.14 Prognosis
2.15 Follow-up and Monitoring of Anti-Inflammatory Response
2.16 Hybrid PET-CMR Imaging
2.17 Outlook
2.18 Conclusion
References
3: Cardiac Amyloidosis
3.1 Introduction
3.1.1 Different Phenotypes of Cardiac Amyloidosis
3.1.1.1 AL Amyloidosis
3.1.1.2 ATTR Amyloidosis
3.1.2 Screening for Cardiac Amyloidosis
3.2 Diagnosis
3.2.1 Endomyocardial Biopsy
3.2.2 Cardiac Magnetic Resonance (CMR) Imaging
3.2.2.1 CMR Diagnosis and Imaging Protocol
3.2.2.2 Late Gadolinium Enhancement (LGE)
3.2.2.3 Quantitative Tissue Characterization with CMR Native T1, T2 and ECV Mapping
3.2.2.4 Differential Diagnosis of AL vs. ATTR Amyloid
3.2.3 Scintigraphy
3.2.3.1 Bone Avid Radiotracers
Imaging Protocols and Interpretation
Diagnostic Accuracy
3.2.3.2 Innervation Radiotracers
3.2.4 Positron Emission Tomography (PET)
3.2.5 Hybrid Imaging: PET/MRI
3.2.6 Diagnostic Algorithm for Diagnosis and Sub-Typing of Cardiac Amyloidosis
3.3 Treatment
3.4 Prognosis
3.5 Conclusion
References
Part III: Ischemic Diseases
4: Molecular Imaging of Vulnerable Plaque
4.1 Introduction
4.2 Biology and Pathogenesis of Atherosclerosis
4.2.1 History
4.2.2 Mechanisms of Atherosclerosis
4.2.2.1 Initiation of Atherosclerosis
Vascular Endothelium and Atherosclerosis
Hemodynamics Forces in Atherosclerosis
Low-Density Lipoprotein Cholesterol
Surface Adhesion Molecules
Foam Cells Formation
Progression of Atherosclerosis
Smooth Muscle Cells and Atherosclerosis
Calcification
Plaque Neoangiogenesis
Innate Immunity Cells in Atherosclerosis
Adaptive Immunity in Atherosclerosis
4.2.3 Complication of Atherosclerosis
4.2.3.1 Inducible Ischemia
4.2.3.2 Plaque Rupture
4.2.3.3 Plaque Erosion
4.3 Metabolism of Glucose in Atherosclerosis
4.3.1 Glucose and Immune Cells